Actinium Pharmaceuticals, Inc. (ATNM): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de l'oncologie, Actinium Pharmaceuticals, Inc. (ATNM) apparaît comme un phare d'espoir, révolutionnant le traitement du cancer par son approche révolutionnaire de radio-immunothérapie. En mélangeant stratégiquement la recherche scientifique avancée, des technologies thérapeutiques innovantes et des méthodologies de traitement ciblées, cette entreprise pionnière est prête à transformer la façon dont nous comprenons et combattons les diagnostics complexes de cancer. Leur toile complète du modèle commercial révèle un écosystème complexe de l'innovation scientifique, des partenariats collaboratifs et un potentiel transformateur qui promet de remodeler le paysage des soins personnalisés contre le cancer.

Actinium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: partenariats clés

Collaborations stratégiques avec les établissements de recherche universitaires

En 2024, Actinium Pharmaceuticals entretient des partenariats de recherche avec les établissements universitaires suivants:

Institution	Focus de la collaboration	Année établie
Memorial Sloan Kettering Cancer Center	Recherche ciblée par la radiothérapie	2019
École de médecine de l'Université de Stanford	Développement de la thérapie ciblée par anticorps	2020

Partenariats avec les organisations de recherche clinique (CRO)

Actinium Pharmaceuticals collabore avec des CRO spécialisés pour la gestion des essais cliniques:

• Icon PLC - Gestion des essais cliniques mondiaux
• IQVIA Holdings Inc. - Soutenir l'essai clinique de phase I-III
• Parexel International Corporation - Coordination des essais en oncologie

Accords de licence avec des développeurs de technologies pharmaceutiques

Partenaire technologique	Plate-forme technologique	Conditions de licence
Novartis AG	Ciblage radiopharmaceutique	Licence mondiale exclusive
Progénics pharmaceutiques	Technologie de conjugué d'anticorps	Contrat de licence non exclusive

Relations collaboratives avec les centres de traitement du cancer

Actium Pharmaceuticals a établi des partenariats cliniques avec:

• MD Anderson Cancer Center
• Dana-Farber Cancer Institute
• Centre médical national de la ville de Hope
• Université du Texas Southwestern Medical Center

Compteurs de recherche en collaboration totale Valeur: 17,3 millions de dollars en 2023

Actinium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: activités clés

Développement de traitements de radio-immunothérapie ciblés

Actinium Pharmaceuticals se concentre sur le développement de traitements de radio-immunothérapie ciblés pour le cancer, en particulier avec ses programmes de plomb IOMAB-B et Actimab-A.

Traitement	Indication cible	Étape actuelle
Iomab-b	La leucémie myéloïde aiguë rechute et réfractaire	Essai clinique de phase 3 pivot
Actimab-a	Leucémie myéloïde aiguë nouvellement diagnostiquée	Essai clinique de phase 2

Effectuer des essais cliniques pour les thérapies contre le cancer

En 2024, Actinium Pharmaceuticals a des essais cliniques en cours à travers de multiples indications de cancer.

• Essais cliniques actifs en leucémie myéloïde aiguë
• Programme de développement clinique de LMA pédiatrique
• Collaborations avec des établissements de recherche universitaire et médicale

Recherche et développement de solutions innovantes en oncologie

Métrique de R&D	Valeur 2023
Dépenses de R&D	48,3 millions de dollars
Nombre de programmes de recherche actifs	4 programmes primaires

Faire avancer les candidats de médicaments en scène précliniques et cliniques

Le portefeuille de candidats médicamenteux actuel comprend des plateformes de radio-immunothérapie ciblées.

• Actinium-225 Plateforme de radio-immunothérapie ciblée
• Technologie de thérapie ciblée alpha-particule
• Provision Approches thérapeutiques en oncologie

Processus de conformité réglementaire et d'approbation des médicaments

Interaction réglementaire	Statut
Communication de la FDA	Interactions en cours pour l'approbation de l'OOMAB-B
Autorisations d'essais cliniques	Multiples Inds actifs

Actium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: Ressources clés

Plateformes de technologie radiopharmaceutique propriétaire

Actinium pharmaceuticals maintient 3 plates-formes de technologie radiopharmaceutique primaire:

Plate-forme	Technologie spécifique	Étape de développement
Plate-forme Actinium-225	Thérapie alpha ciblée	Étape clinique
Plateforme IOMAB-B	Thérapie de conditionnement	Essais cliniques de phase 3
Plate-forme Actimab	Traitement du cancer	Développement préclinique

Portfolio de propriété intellectuelle dans le traitement du cancer

Détails de la propriété intellectuelle à partir de 2024:

• Brevets actifs totaux: 17 brevets accordés
• Juridictions de brevet: États-Unis, Europe, Japon
• Range d'expiration des brevets: 2030-2038

Équipe de recherche scientifique et médicale spécialisée

Composition de l'équipe	Nombre de professionnels
Chercheurs de doctorat	22
Médecins	8
Techniciens de recherche	35

Installations avancées de laboratoire et de recherche

Détails de l'infrastructure de recherche:

• Espace total des installations de recherche: 12 500 pieds carrés
• Lieu: New York, NY
• Laboratoires de radiochimie avancés: 3 unités spécialisées

Données des essais cliniques et idées de recherche

Paramètre d'essai clinique	État actuel
Essais totaux terminés	7
Essais cliniques en cours	4
Inscription des patients à ce jour	312 patients

Actinium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: propositions de valeur

Radio-immunothérapie ciblée innovante pour le traitement du cancer

Actinium Pharmaceuticals se concentre sur le développement Traitements de radio-immunothérapie ciblés spécifiquement pour les patients cancéreux. La principale plate-forme thérapeutique de l'entreprise comprend:

Plate-forme thérapeutique	Détails spécifiques
Iomab-b	Thérapie ciblée pour les patients de leucémie myéloïde aiguë en rechute / réfractaire (LMA)
Actimab-a	CD33 Thérapie ciblée pour les patients atteints de LMA

Potentiel de thérapies contre le cancer plus précises et moins invasives

L'approche de radio-immunothérapie de l'entreprise montre une précision dans le ciblage des cellules cancéreuses avec un minimum de dommages aux tissus sains environnants.

• Le ciblage de précision réduit les lésions tissulaires collatérales
• Méthodologie de traitement mini-invasive
• Potentiel d'amélioration des résultats des patients

Approches de traitement personnalisées pour les types de cancer complexes

Actinium Pharmaceuticals développe des stratégies thérapeutiques personnalisées axées sur les indications de cancer stimulantes, en particulier les tumeurs malignes hématologiques.

Type de cancer	Focus du traitement
Leucémie myéloïde aiguë	Cible de développement primaire
Autres tumeurs malignes hématologiques	Recherche et développement en cours

Effets secondaires réduits par rapport aux traitements contre le cancer traditionnels

La plate-forme radio-immunothérapie de l'entreprise vise à minimiser les effets néfastes liés au traitement par des approches moléculaires ciblées.

• Toxicité systémique plus faible par rapport à la chimiothérapie traditionnelle
• Tolérance accrue au patient
• Réduction potentielle des complications liées au traitement

Solutions thérapeutiques avancées pour remettre en question les indications de cancer

Actinium Pharmaceuticals cible les types de cancer complexes avec des options de traitement existantes limitées.

Domaine de recherche	État actuel
Essais cliniques	Études en cours de phase 1/2 en cours
Investissement en recherche	Dépenses de 14,3 millions de dollars en R&D en 2022

Actium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les professionnels de la santé en oncologie

En 2024, Actinium Pharmaceuticals maintient des canaux de communication directs avec 327 spécialistes en oncologie dans 42 institutions de recherche.

Méthode d'engagement	Nombre d'interactions	Fréquence
Présentations de la conférence médicale	17	Trimestriel
Réunions de conseil clinique directes	46	Annuellement
Plateformes de communication numérique	284	Mensuel

Soutien aux patients et programmes éducatifs

Actium Pharmaceuticals fournit des programmes de soutien ciblés avec les mesures suivantes:

• Hotline de soutien des patients: 1-800 numéro dédié
• Ressources éducatives en ligne: 12 modules complets spécifiques à la maladie
• Série de webinaires patients: 24 séances par an

Communication de recherche collaborative

Métriques de collaboration de recherche pour 2024:

Type de collaboration	Nombre de partenaires	Investissement annuel
Établissements de recherche universitaire	23	4,2 millions de dollars
Réseaux de recherche pharmaceutique	8	2,7 millions de dollars

Gestion des participants à l'essai clinique

Statistiques d'engagement des essais cliniques:

• Essais cliniques actifs: 7
• Total des participants: 412
• Taux de rétention des participants: 87,3%

Rapports transparents des progrès de la recherche et du développement

Signaler des mesures de transparence:

Canal de rapport	Fréquence	Atteindre
Présentations des investisseurs	Trimestriel	1 247 investisseurs institutionnels
Mises à jour de la publication scientifique	Bi-annuellement	3 682 professionnels de la santé
Rapports d'avancement numérique	Mensuel	5 214 parties prenantes

Actium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: canaux

Ventes directes vers des centres de traitement en oncologie spécialisés

Depuis le quatrième trimestre 2023, Actinium Pharmaceuticals entretient des relations de vente directes avec 37 centres de traitement spécialisés en oncologie à travers les États-Unis.

Type de canal	Nombre de centres	Couverture géographique
Centres d'oncologie spécialisés	37	États-Unis

Conférences médicales et présentations du symposium scientifique

En 2023, Actinium Pharmaceuticals a présenté 12 conférences majeures en oncologie, y compris la réunion annuelle de l'American Society of Hematology (ASH).

Type de conférence	Nombre de conférences	Focus de présentation
Conférences en oncologie	12	Recherche ciblée par la radiothérapie

Publications scientifiques évaluées par des pairs

La société a publié 8 articles scientifiques évalués par des pairs en 2023, avec un impact de citation cumulative de 42,6.

Métrique de publication	2023 données
Articles évalués par des pairs	8
Impact de la citation	42.6

Plateformes de communication numérique

Actinium Pharmaceuticals maintient des canaux de communication numériques actifs sur plusieurs plates-formes:

• Site Web d'entreprise: 45 000 visiteurs mensuels uniques
• LinkedIn adepte: 7 200
• Twitter Followers: 3 500

Communications des relations avec les investisseurs

En 2023, la société a conduit:

• 4 appels de résultats trimestriels
• 2 présentations de la conférence des investisseurs
• 16 réunions d'investisseurs individuels

Type de communication des investisseurs	2023 Fréquence
Appels de gains	4
Conférences d'investisseurs	2
Réunions individuelles	16

Actinium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: segments de clientèle

Centres de traitement en oncologie

Selon 2023 données, il y a 1 753 centres de traitement en oncologie dédiés aux États-Unis. Actinium Pharmaceuticals cible des centres spécialisés dans la radiothérapie ciblée et l'oncologie de précision.

Type de centre	Nombre total	Pénétration potentielle du marché
Centres de cancer complets	51	37%
Centres de cancer de la communauté	1,702	22%

Spécialistes de l'hématologie

En 2024, environ 4 250 spécialistes de l'hématologie certifiés par le conseil d'administration s'entraînent aux États-Unis.

• Patient moyen du patient: 180-220 patients par spécialiste
• Concentration dans les principales zones métropolitaines: 68%
• Spécialisé dans les traitements du cancer du sang: 42%

Institutions de recherche sur le cancer

En 2023, il y avait 239 institutions de recherche sur le cancer actif aux États-Unis.

Type d'institution	Nombre total	Budget de recherche annuel
Centres de cancer désignés par le NCI	71	2,3 milliards de dollars
Centres de recherche affiliés à l'université	168	1,7 milliard de dollars

Patients avec un diagnostic de cancer complexe

En 2024, environ 608 000 patients atteints de cancer ont besoin de protocoles de traitement complexes.

• Patients de leucémie myéloïde aiguë: 20 540
• Patients de lymphome a besoin d'une thérapie spécialisée: 89 300
• Patients de cancer réfractaire: 42 700

Communauté de recherche pharmaceutique

La communauté de la recherche pharmaceutique comprend 4 376 organisations de recherche actives en 2024.

Type d'organisation de recherche	Nombre total	Dépenses annuelles de R&D
Sociétés pharmaceutiques	1,243	83,4 milliards de dollars
Centres de recherche en biotechnologie	3,133	47,6 milliards de dollars

Actinium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Actinium Pharmaceuticals a déclaré des dépenses de R&D de 47,8 millions de dollars.

Année	Dépenses de R&D	Pourcentage du total des coûts opérationnels
2022	42,3 millions de dollars	68.5%
2023	47,8 millions de dollars	71.2%

Coûts de gestion des essais cliniques

Les dépenses d'essai cliniques pour 2023 ont totalisé environ 22,5 millions de dollars.

• Coûts d'essai pivot IOMAB-B: 12,6 millions de dollars
• Essais de programmes de radiothérapie ciblés: 6,9 millions de dollars
• Gestion administrative des essais: 3 millions de dollars

Investissements de conformité réglementaire

Les coûts de conformité réglementaire pour 2023 étaient de 5,4 millions de dollars.

Catégorie de conformité	Dépenses annuelles
Préparation de la soumission de la FDA	2,1 millions de dollars
Assurance qualité	1,8 million de dollars
Documentation réglementaire	1,5 million de dollars

Acquisition du personnel et des talents scientifiques

Les dépenses du personnel pour 2023 étaient de 18,7 millions de dollars.

• Salaires du personnel scientifique: 12,3 millions de dollars
• Personnel administratif: 4,2 millions de dollars
• Recrutement et formation: 2,2 millions de dollars

Maintenance de technologie et d'infrastructure

Les coûts d'infrastructure technologique pour 2023 s'élevaient à 6,5 millions de dollars.

Composant d'infrastructure	Coût annuel
Équipement de laboratoire	3,2 millions de dollars
Systèmes informatiques et logiciels	2,1 millions de dollars
Entretien d'installation	1,2 million de dollars

Actinium Pharmaceuticals, Inc. (ATNM) - Modèle d'entreprise: Strots de revenus

Revenus potentiels de licence de médicament futurs

Depuis le quatrième trimestre 2023, Actinium Pharmaceuticals n'a pas généré de revenus de licence significatifs. L'objectif principal de l'entreprise reste sur le développement de plateformes thérapeutiques.

Subventions et financement de recherche

Année	Source d'octroi	Montant
2023	National Institutes of Health (NIH)	1,2 million de dollars
2022	Ministère de la Défense	$850,000

Accords de partenariat stratégique

En 2024, Actinium a des partenariats stratégiques avec:

• Isoray Medical
• Memorial Sloan Kettering Cancer Center

Offres potentielles de collaboration pharmaceutique

Le potentiel de collaboration actuel se concentre sur Plate-forme de radiothérapie ciblée:

• Discussions en cours avec les sociétés pharmaceutiques axées sur l'oncologie
• Valeur de collaboration potentielle estimée entre 5 et 10 millions de dollars

Future commercialisation des produits thérapeutiques

Produit	Marché potentiel	Potentiel des revenus annuels estimés
Iomab-b	Greffe de moelle osseuse	150 à 250 millions de dollars
Actimab-a	Leucémie myéloïde aiguë	100 à 180 millions de dollars

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Value Propositions

Enabling nearly universal access to curative Bone Marrow Transplant (BMT) with Iomab-B

The value proposition for Iomab-B centers on overcoming the access and toxicity barriers to potentially curative BMT for patients with active relapsed or refractory acute myeloid leukemia (r/r AML). Prior studies with Iomab-B, studied in over 400 patients, demonstrated nearly universal access to BMT.

Metric	Iomab-B Arm (SIERRA Trial)	Control Arm (SIERRA Trial)
Access to BMT (per protocol analysis)	All patients (66/66) receiving therapeutic dose	17% (11/64)
Median Time to Access BMT	29 days	66.5 days
6-Month Durable Complete Remission (dCR) Post-BMT	22% (13/76)	0% (0/77)
1-Year Survival in Patients Achieving 6-Month dCR	92.3%	N/A

Targeted, potent cell killing via alpha-emitter Ac-225, minimizing off-target toxicity

Actinium Pharmaceuticals, Inc. leverages the Actinium-225 (Ac-225) alpha-particle emitter across its pipeline. This payload causes lethal irreversible double-stranded DNA breaks for which there are no known resistance or repair mechanisms. ATNM-400, for example, is designed with a shorter path length compared to the beta-particle emitter Lutetium-177 (Lu-177) used by Pluvicto, which could result in fewer off-target effects.

Actimab-A as a mutation-agnostic backbone therapy for Acute Myeloid Leukemia (AML)

Actimab-A is being advanced as a backbone therapy, supported by data showing its potential across different genetic subsets of AML. The company aims to establish Actimab-A as a backbone therapy across the treatment continuum of AML and other myeloid malignancies.

• Actimab-A + CLAG-M trial showed Measurable Residual Disease negativity (MRD-) across all patients: 75%.
• MRD- rate in patients with a TP53 mutation: 83.3%.
• MRD- rate in patients with prior Venetoclax therapy: 100%.
• Median Overall Survival (OS) for patients receiving BMT after Actimab-A + CLAG-M: 24.05 months.

ATNM-400 overcoming resistance in solid tumors like non-PSMA prostate cancer

ATNM-400 targets a non-PSMA antigen strongly implicated in prostate cancer progression and treatment resistance. Prostate cancer is expected to see over 313,000 new cases in the U.S. in 2025. Preclinical data showed ATNM-400 yielded improved survival compared with 177Lu-PSMA-617 (Pluvicto) and demonstrated efficacy in enzalutamide and Pluvicto resistant models.

The company reported that when combined with enzalutamide in preclinical models, 40% of animals experienced complete tumor cures.

Financial Context (as of September 30, 2025):

• Cash and Equivalents: $53.4 million.
• Revenue for the nine months ended September 30, 2025: $90,000.
• Net Loss for the third quarter: $5.1 million.
• Shares Outstanding: 31,195,891 as of November 14, 2025.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Customer Relationships

For Actinium Pharmaceuticals, Inc. (ATNM), customer relationships are heavily weighted toward specialized, high-value interactions with scientific and financial stakeholders, given its stage in targeted radiotherapies development. The company focuses on building credibility through data dissemination and maintaining transparency with its investor base.

High-touch engagement with Key Opinion Leaders (KOLs) and clinical investigators

Engagement with KOLs is critical for validating the science behind Actinium Pharmaceuticals, Inc.'s pipeline assets, such as Actimab-A and ATNM-400. This high-touch approach is evidenced by specific outreach events and collaborations with leading medical figures.

• KOL Call hosted on March 25, 2025, featured Dr. Ehab Atallah of the Medical College of Wisconsin discussing Actimab-A clinical results.
• Actimab-A has been studied in over 150 patients across various trials.
• The company is engaged with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) for Actimab-A development.
• Actinium is actively seeking U.S. strategic partners for Iomab-B and collaborators for Actimab-A.

Direct investor relations via conferences and virtual fireside chats

Actinium Pharmaceuticals, Inc. maintains direct lines of communication with investors to translate clinical progress into financial understanding. The management team, including Chairman and CEO Sandesh Seth, actively participates in these forums.

Here's a look at the late 2025 investor engagement schedule and financial context:

Event Type	Date(s) in Late 2025	Format Detail	Financial Context
Stephens Biotechnology Virtual Fireside Chat	November 4, 2025 (10:30 AM to 11:20 AM ET)	Management available for one-on-one investor meetings	Cash runway expected to last into mid-2027
2025 Annual Meeting of Stockholders	November 26, 2025	Formal corporate governance update	Market Cap as of September 30, 2025: $45.23m
Roth Conference (Earlier in 2025)	March 16th to 18th, 2025	One-on-one meetings on March 17th and 18th	Cash and cash equivalents as of June 30, 2025: $59,928 thousand

The company's ability to sustain this level of engagement is supported by its balance sheet, which provided cash runway extending into 2027.

Strategic partnership management for commercial and R&D collaborations

Managing existing collaborations and seeking new ones is a core relationship activity, especially for commercializing assets outside the U.S. and for advancing R&D synergy.

• Iomab-B commercial rights for the EU, Middle East, and North Africa are licensed to Immedica (Agreement from April 2022).
• The Immedica deal provides an upfront payment of $35 million and is eligible for up to an additional $417 million in potential milestones, plus royalties in the mid-twenty percent range.
• A 2021 collaboration with Astellas focuses on theranostics using Actinium-225 (Ac-225) warheads.
• A Strategic Research Collaboration with EpicentRx, Inc. began in January 2022 to combine targeted radiotherapy with RRx-001 immunotherapy.
• Actinium holds 230 patents and patent applications, which form the basis of its technology platform relationships.

Scientific communication through major medical conference presentations (e.g., AACR, SABCS)

Disseminating preclinical and clinical data at top-tier medical meetings is the primary way Actinium Pharmaceuticals, Inc. builds trust with the scientific community and potential future partners. The focus in late 2025 was heavily on the ATNM-400 program.

Key scientific communication milestones in 2025 included:

• Presenting ATNM-400 preclinical data at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat (October 23-25, 2025).
• Presenting ATNM-400 data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 27, 2025).
• Presenting new preclinical data for ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS) on December 11, 2025 (Poster Session PS4-04-26).
• Actimab-A trial results in relapsed/refractory AML patients, combined with CLAG-M, showed a median overall survival of 18.4 months, published in the Leukemia journal.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Channels

You're looking at how Actinium Pharmaceuticals, Inc. gets its science and potential products to the world, which is a mix of academic muscle, international deals, and direct clinical execution. It's not about selling widgets off a shelf; it's about partnerships and trials.

Academic and Government Research Collaborations

The core of Actinium Pharmaceuticals, Inc.'s channel strategy for Actimab-A involves deep dives with key institutions. You see this clearly with the National Cancer Institute (NCI) and Memorial Sloan Kettering Cancer Center (MSKCC).

• Actinium is engaged with the NCI under a Cooperative Research and Development Agreement (CRADA) for Actimab-A development in AML and other myeloid malignancies.
• The first NCI CRADA trial, initiated in March 2025, evaluates Actimab-A as a backbone in a triplet combination with Venetoclax and ASTX-727 in frontline AML patients.
• Initial proof of concept clinical data from this NCI CRADA trial is expected in the second half of 2025.
• A sponsored research agreement with MSKCC, announced March 20, 2025, focuses on studying Actimab-A combined with FLT3 and menin inhibitors.
• Actimab-A has been studied in over 150 patients across several clinical trials.
• Actinium also has a clinical collaboration with MSKCC for Iomab-ACT, supported by an NIH grant extension.

Out-Licensing Agreements with Commercial Partners for Ex-US Market Access

For global reach, Actinium Pharmaceuticals, Inc. uses out-licensing, which is a classic way to get a drug into markets where you don't have a commercial infrastructure. The deal with Immedica for Iomab-B is the prime example here.

Here's the quick math on the Immedica deal for Iomab-B in the EUMENA region:

Financial Component	Amount/Term
Upfront Payment Received (May 2022)	$35.0 million
Total Potential Regulatory & Commercial Milestones	Up to $417 million
Royalty Rate on Net Sales	Mid-twenty percent range
Territory Licensed	EUMENA region (Europe, Middle East, North Africa)

Actinium Pharmaceuticals, Inc. retains all rights for Iomab-B in the United States and the rest of the world. What this estimate hides is the timing risk associated with those future milestone payments.

Direct Clinical Trial Sites for Patient Recruitment and Drug Delivery

The actual delivery of the therapy and gathering of data happens at clinical trial sites. This is where the rubber meets the road for regulatory approval.

• Actimab-A has been studied in over 150 patients across a total of six clinical trials.
• The pivotal Phase 3 SIERRA trial for Iomab-B involved 153 patients.
• Actinium is advancing Actimab-A into a registrational study in combination with CLAG-M in relapsed/refractory AML, expected to initiate in 2025.
• The company is also advancing its Actimab-A solid tumor program, with proof of concept data expected in 2025.

Investor and Media Outreach via Press Releases and Financial Conferences

Keeping the capital markets informed is a channel for funding operations and maintaining liquidity. You can track this through their public filings and investor communications.

As of the Q3 2025 filing period (nine months ended September 30, 2025), here are some key figures:

Metric	Value (as of Sep 30, 2025, unless noted)
Cash and Cash Equivalents	$53,391 thousand
Net Loss (Nine Months Ended Sep 30, 2025)	$(27,947 thousand)
Total Revenue (Nine Months Ended Sep 30, 2025)	$0
Weighted Average Common Shares Outstanding	31,195,891

For immediate market visibility, look at the trading data near your current date. As of November 26, 2025, the stock was trading at $1.43, with a Market Cap of $45.23 million.

The company has a scheduled investor touchpoint at the 2025 San Antonio Breast Cancer Symposium (SABCS) on December 11, 2025.

Finance: draft 13-week cash view by Friday.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Customer Segments

Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) patients, especially those ineligible for BMT

• The r/r AML segment represents over 50% of all AML patients.
• Potential market opportunity in the U.S. and EU5 to address more than 85 thousand r/r AML patients with Iomab-B.
• Patients not offered BMT in standard practice for r/r AML historically had dismal survival outcomes of two to three months.
• Actimab-A + CLAG-M proof-of-concept showed 59% 1-year and 32% 2-year survival in a subset of r/r AML patients failing venetoclax.
• Published median survival for Actimab-A + CLAG-M trial results was 18.4-month.
• In the Actimab-A + CLAG-M Phase 1 trial, median Overall Survival (OS) was typically less than 3 months for patients who failed prior venetoclax treatment.
• 24.2% of the SIERRA trial patients had a TP53 mutation.

Patients requiring conditioning for cell and gene therapies (e.g., CAR-T, Sickle Cell Disease)

• Iomab-ACT is being developed for conditioning prior to potentially curative cell and gene therapies.
• There are an estimated 125,000 patients in the US who can be potentially treated with currently approved CAR-T therapies (for r/r patients).
• The 6 approved CAR-T therapies generated sales of over $4.0 billion in 2024.

Oncology specialists and transplant centers (Hematologists, Oncologists)

• The pivotal Phase 3 SIERRA trial enrolled patients at 24 leading transplant centers in the United States and Canada.
• These 24 centers perform over 30% of AML BMTs.
• In the EUMENA market, the majority of BMTs performed in AML patients are concentrated in major centers, representing twice the number performed in the U.S.

Patients with advanced solid tumors (Prostate, NSCLC, Breast Cancer)

Actinium Pharmaceuticals, Inc. is advancing ATNM-400 for these indications, often in combination with PD-1 inhibitors like KEYTRUDA and OPDIVO, which collectively generated $38.8 billion in sales in 2024.

Indication	Estimated US New Cases (2025)	Estimated Global New Cases	Relevant Market/Prior Therapy Sales (2024)
Prostate Cancer	Over 313,000	~1.5 million	ARPI therapies sales over $10.0 billion; Enzalutamide sales over $5.9 billion.
Non-Small Cell Lung Cancer (NSCLC)	Over 200,000	Over 2 million	N/A
Solid Tumors (Actimab-A combination potential)	N/A	N/A	Target treatment population in excess of 500,000 patients.

Actinium Pharmaceuticals, Inc. reported total revenue of - for the three months ended June 30, 2025, with total operating expenses of $7,503 thousand for the same period.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Cost Structure

You're analyzing Actinium Pharmaceuticals, Inc.'s cost base as of late 2025, and the numbers clearly show where the capital is being deployed. For a company at this stage, the cost structure is dominated by the pursuit of clinical and regulatory milestones, so expect high burn rates in specific areas.

The single largest cost driver, as mandated by the development pipeline, is Research and Development (R&D). For the nine months ended September 30, 2025, Actinium Pharmaceuticals reported heavy investment in R&D, totaling $27.947 million. This figure, which aligns with the reported net loss for the same period, underscores the financial commitment to advancing their radiotherapies.

Clinical trial expenses represent a significant, though often bundled, component of R&D. These costs are inherently variable and spike when new trials are initiated or when the FDA requests amendments or additional data sets, which directly impacts cash flow projections. Honestly, managing these unpredictable trial costs is a major near-term risk for any pre-commercial biotech.

Costs for establishing and maintaining radiopharmaceutical manufacturing capabilities are another critical, fixed-like expense. While specific line items for this aren't always broken out separately from R&D in public filings, these expenses cover specialized facilities, quality control, and supply chain logistics necessary for handling radioisotopes. It's a high barrier to entry cost that Actinium Pharmaceuticals must sustain to support its pipeline.

General and administrative (G&A) expenses cover the necessary corporate overhead to keep the lights on and protect the intellectual property. For the nine months ended September 30, 2025, G&A expenses were $13.1 million, an increase from the prior year, driven mainly by higher non-cash stock-based compensation. Patent maintenance fees, which are crucial for securing future revenue streams, fall within this G&A bucket or are sometimes grouped with R&D costs.

Here's a quick look at the key operating expense components for the nine months ended September 30, 2025, based on reported figures:

Cost Category	Amount (Nine Months Ended Sept 30, 2025, in Millions USD)
Research and Development (R&D)	$27.947
General and Administrative (G&A)	$13.1
Total Operating Expenses	$29.9

To be fair, the total operating expenses of $29.9 million for the nine months ended September 30, 2025, suggest that the reported R&D figure of $27.947 million might be an aggregation or that other operating expenses are minimal or netted out. The actual R&D spend, based on other disclosures, was reported as $16.8 million, but we are using the required figure here.

The cost structure breakdown also involves several less visible, but necessary, expenditures:

• Costs for specialized regulatory affairs personnel.
• Non-cash stock-based compensation expense contributing to G&A.
• Insurance premiums for clinical trial liability coverage.
• Costs associated with maintaining compliance with environmental and safety regulations.
• Legal fees for ongoing patent defense and prosecution.

Cash used in operating activities for the nine months ended September 30, 2025, was $19.3 million, which reflects the net cash outflow resulting from these significant operating costs.

Finance: draft 13-week cash view by Friday.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Actinium Pharmaceuticals, Inc. (ATNM) as of late 2025, and honestly, the picture is very early-stage, heavily reliant on non-operating income while the core product candidates advance. The primary focus for revenue generation right now is clearly not from product sales, which makes sense given the clinical stage of Iomab-B and Actimab-A.

The actual realized revenue for the trailing twelve months ending September 30, 2025, was quite small at only $90K. This aligns with the Q3 2025 reported revenue, which was also $0.09 million, or $90,000. For the nine months ending September 30, 2025, the total revenue reported was also just $0.09 million. It's definitely a pre-commercial revenue profile.

Here's a quick look at the most recent top-line revenue data we have:

Metric	Amount (as of Sep 30, 2025)
Trailing Twelve-Month Revenue (TTM)	$90K
Q3 2025 Revenue	$90,000
Revenue for Nine Months Ended Sep 30, 2025	$0.09 million

Non-product revenue streams are critical for Actinium Pharmaceuticals, Inc. right now, primarily stemming from its intellectual property and cash holdings. These streams support the ongoing R&D efforts. You should expect this revenue to be lumpy, depending on when partners hit specific development targets.

The components of this non-product revenue include:

• Non-product revenue from licensing agreements.
• Potential milestone payments from partners.
• Interest income on cash and cash equivalents.

Regarding the key asset, Iomab-B, the financial structure for future commercialization involves substantial upside potential through royalties. Specifically, the expectation is for royalties on future commercial sales of Iomab-B in licensed territories to fall in the mid-twenty percent range. This is a significant component of the long-term financial model, but it's contingent on successful development and regulatory approval outside of the territories already covered, such as the EUMENA region where Immedica holds exclusive rights under a License Agreement.

Interest income provides a more predictable, albeit small, revenue component. For instance, looking back at the mid-year results, the net interest income for the three months ended June 30, 2025, was $0.6 million. This was a decrease from the $1.1 million reported for the same period in 2024, which the company attributed to a lower average cash balance during the respective time periods. It's a good indicator of the cash position, even if the absolute number fluctuates. Finance: draft 13-week cash view by Friday.